Subscribe to RSS
DOI: 10.1055/s-2000-7732
Tau-Protein-Spiegel in der Diagnostik der Alzheimer-Demenz
Publication History
Publication Date:
31 December 2000 (online)
![](https://www.thieme-connect.de/media/fdn/200010/lookinside/thumbnails/10.1055-s-2000-7732-1.jpg)
Zusammenfassung:
Die Konzentration des Tau-Proteins im Liquor zerebrospinalis wurde bei 55 Patienten mit Alzheimer-Demenz (AD), 18 Patienten mit vaskulärer Demenz (VD), 19 Patienten mit Demenzen anderer Ursache und 14 altersangeglichenen depressiv Erkrankten bestimmt. Im Gruppenvergleich bestanden bei den AD-Patienten signifikant (p < 0,05) erhöhte Tau-Spiegel (564,5 ± 275,5 pg/ml) gegenüber allen anderen Untersuchungsgruppen (VD: 406,5 ± 263,9 pg/ml; andere Demenzformen: 275,0 ± 135,4 pg/ml; depressiv Erkrankte: 212,9 ± 115,6 pg/ml). Allerdings zeigten die Tau-Spiegel innerhalb der AD-Gruppe eine hohe Spannweite (163,2 pg/ml - 1200 pg/ml); bei AD-Patienten mit niedrigen Werten unterhalb der 25 %-Quartile - darunter ein hoher Anteil von Patienten mit präsenilem Beginn - waren ähnliche Tau-Spiegel wie bei den nicht demenziell beeinträchtigten depressiv Erkrankten nachweisbar. Signifikante Korrelationen zwischen der Tau-Konzentration und klinischen Variablen wie Lebensalter, Ersterkrankungsalter, Krankheitsdauer, Schweregrad der demenziellen Symptomatik und magnetresonanztomographisch bestimmten hirnvolumetrischen Veränderungen bestanden innerhalb der AD-Patientengruppe nicht. Weder ein Einfluss des Apo-E-Genotyps noch einer eventuellen psychotropen Medikation auf die Tau-Spiegel konnte bei den AD-Patienten festgestellt werden. Übereinstimmend mit anderen Autoren bestätigen unsere Ergebnisse erhöhte Tau-Spiegel bei der AD. Im Gruppenvergleich gilt dieser Befund auch gegenüber der VD und anderen Demenzformen. Allerdings sind erhöhte Tau-Spiegel bei einem Teil der AD-Patienten nicht nachweisbar; ein Befund, der in weiteren Studien abzuklären ist.
Cerebrospinal Fluid Protein Tau Levels in the Differential Diagnosis of Alzheimer's Disease:
Tau protein concentration in cerebrospinal fluid was determined in 55 patients with Alzheimer's disease (AD), 18 patients with vascular dementia (VD), 19 patients with dementia caused by other disorders and 14 patients with major depression. Significantly (p < 0.05) elevated protein tau concentrations were found in AD patients (564.5 ± 275.5 pg/ml) compared to all other patient groups (VD: 406.5 ± 263.9 pg/ml; other dementia: 275.0 ± 135.4 pg/ml; depression: 212.9 ± 115.6 pg/ml). However, tau levels in AD patients covered a broad range (163.2 pg/ml - 1200 pg/ml). AD patients with tau levels below the 25 %-percentile of the distribution (among them a high percentage of patients with presenile onset) showed tau levels similar to those of the patients with late life depression. No significant correlations between tau levels and clinical variables such as severity of dementia, age, age of onset, duration of illness, and cerebral changes as assessed by volumetric magnetic resonance imaging could be demonstrated. Similarly, we could not find an influence of either APO-E genotype or psychotropic medication on the tau levels in AD patients. In accordance with other studies our results confirm elevated tau levels in AD compared to elderly not demented control subjects. Comparing groups, this finding applies as well with respect to VD and other dementing disorders. However, elevated tau levels cannot be detected in a subgroup of AD patients. This finding needs to be further investigated in future studies.
Literatur
- 1 Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, Raiha I, Sourander L, Winblad B, Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community follow up study. J Neurol Neurosurg Psychiatry. 1998; 64 298-305
- 2 Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology. 1999; 53 1488-1494
- 3 Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, Seiki H, Takase S, Clark C M, Lee V MY et al. Tau in cerebrospinal fluid: a potential diagnostik marker in Alzheimer's disease. Ann Neurol. 1995; 38 649-652
- 4 Arai H, Higuchi S, Sasaki H. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Gerontology. 1997; 43 2-10
- 5 Arai H, Morikawa Y, Higuchi M, Matsui T, Clark C M, Miura M, Machida N, Lee V, Trojanowski J Q, Sasaki H. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997; 236 262-264
- 6 Arai H, Nakagawa T, Kosaka Y, Higuchi M, Matsui T, Okamura N, Tashiro M, Sasaki H. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired individuals. Alzheimer's Research. 1997; 3 211-213
- 7 Arai H, Satoh-Nakagawa T, Higuchi M, Morikawa Y, Miura M, Kawakami H, Seki H, Takase S, Sasaki H. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci Lett. 1998; 256 174-176
- 8 Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid - a biochemical marker for axonal degeneration in Alzheimer disease. Mol Chem Neuropathol. 1995; 26 231-245
- 9 Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund L O. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipo-protein E allele epsilon 4 during 14 months follow-up. Neurosci Lett. 1996; 214 163-166
- 10 Buch K, Riemenschneider M, Bartenstein P, Willoch F, Müller U, Schmolke M, Nolde T, Steinmann C, Guder W G, Kurz A. Tau-Protein - Ein potentieller biologischer Indikator zur Früherkennung der Alzheimer-Krankheit. Nervenarzt. 1998; 69 379-385
- 11 Folstein M F, Folstein S E, McHugh P R. ‘Mini Mental State’. A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res. 1975; 12 189-198
- 12 Galasko D, Chang L, Motter R, Clark C M, Kaye J, Knopman D, Thomas R, Kholodenko D et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotyp. Arch Neurol. 1998; 55 937-945
- 13 Golombowski S, Müller-Spahn F, Romig H, Mendla K, Hock C. Dependence of cerebrospinal fluid tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci Lett. 1997; 225 213-215
- 14 Green A JE, Harvey R J, Thompson E J, Rossor M N. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett. 1999; 259 133-135
- 15 Hampel H, Bürger K, Padberg F, Bahro M. Aktuelle Möglichkeiten und Perspektiven der Liquoruntersuchung bei der Alzheimer Demenz. In: Förstl H, Bickel H, Kurz A (Hrsg.). Alzheimer Demenz. Grundlagen, Klinik und Therapie Berlin, Heidelberg, New York: Springer 1999: 153-166
- 16 Hesse C, Rosengren L, Vanmechelen E, Vanderstichele E, Jensen C, Davidsson P, Blennow K. Cerebrospinal fluid (CSF) biochemical markers for Alzheimer's disease evaluated in repeated CSF samples after acute ischaemic stroke. 1999 (submitted)
- 17 Hock C, Golombowski S, Naser W, Müller-Spahn F. Increased levels of τ protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Ann Neurol. 1995; 37 414-415
- 18 Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt H C, Riemenschneider M, De Deyn P P, Bancher C, Cras P, Wiltfang J, Metha P D, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H. Improved discrimination of AD patients using β-amyloid (1 - 42) and tau levels in CSF. Neurology. 1999; 52 1555-1562
- 19 Ishiguro K, Ohno H, Arai H, Yamagouchi H, Urakami K, Park J, Sato K, Koho H, Imahori K. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett. 1999; 270 91-94
- 20 Jellinger K A. Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol. 1996; 91 219-220
- 21 Jensen M, Basun H, Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett. 1995; 186 189-191
- 22 Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ 1 - 40, and Aβ 1 - 42(43) in Alzheimer's disease: a study in Japan. Ann Neurol. 1998; 44 17-26
- 23 Kosunen O, Soininen H, Paljärvi L et al. Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol. 1996; 91 185-193
- 24 Lindh M, Blomber M, Jensen M, Basun H, Lannfelt L, Engvall B, Scharnagel H, Marz W, Wahlund L O, Cowburn R F. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci Lett. 1997; 229 85-88
- 25 Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. Stroke. 1983; 14 399-401
- 26 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 1984; 34 939-965
- 27 Mecocci P, Cherubini A, Bregnocchi M, Chionne F, Cecchetti R, Lowenthal D T, Senin U. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease. Alzheimer Dis Assoc Disord. 1998; 12 211-214
- 28 Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R, Usami M, Shoij M, Maruyama S, Hirai S. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequences in tau. Neurosci Lett. 1995; 186 181-183
- 29 Morikawa Y, Arai H, Matsushita S, Kato M, Higuchi S, Miura M, Kawakami H, Higuchi M, Okamura N, Tashiro M, Matsui T, Sasaki H. Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. Alcohol Clin Exp Res. 1999; 4 575-577
- 30 Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, Olson D, Southwick P, Wolfert R, Munroe B, Lieberburg I, Seubert P, Schenk D. Reduction of β-amyloid-peptid 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995; 38 643-648
- 31 Munroe W, Southwick P C, Chang L, Scharre D W, Echols C L, Fu P C, Whaley J M, Wolfert R L. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci. 1995; 25 207-217
- 32 Nishimura T, Takeda M, Nakamura Y, Yosbida Y, Arai H, Sasaki H, Shouji M, Hirai S, Khise K. et al . Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find Exp Clin Pharmacol. 1998; 20 227-235
- 33 Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, Weber T, Kretzschmar H A, Poser S. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett. 1997; 225 210-212
- 34 Pantel J, Schröder J, Schmitt R, Schad L R, Knopp M V, Geißler M, Uhde W H, Blüml S, Friedlinger M, Klemenz M, Essig M, Sauer H. Quantitative Magnetresonanztomographie und Schweregrad der Defizite bei der Demenz vom Alzheimer-Typ. Nervenarzt. 1996; 67 46-52
- 35 Pantel J, Schröder J, Schad L R, Friedlinger M, Knopp M V, Schmitt R, Geissler M, Blüml S, Essig M, Sauer H. Quantitative magnetic resonance imaging and neuropsychological functions in dementia of the Alzheimer type. Psychol Med. 1997; 27 221-229
- 36 Reisberg B, Ferris S H, de Leon M J, Crook T. The global deterioration scale (GDS): an instrument for the assessment of primary degenerative dementia (PDD). Am J Psychiatry. 1982; 139 1136-1139
- 37 Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder W G. Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase. Lancet. 1997; 350 784
- 38 Roman G C, Tatemichi T K, Erkinjuntti T, Cummings J L, Masdeu J C, Garcia J H, Amaducci L, Orgogozo J M, Brun A et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993; 43 250-260
- 39 Schröder J, Pantel J, Ida N, Essig M, Hartmann T, Knopp M V, Schad L R, Sandbrink R, Sauer H, Masters C L, Beyreuther K. Cerebral changes and cerebrospinal fluid β-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol Psychiatry. 1997; 2 505-507
- 40 Schröder J, Pantel J. Morphologische und funktionelle Bildgebung. In: Förstl H, Bickel H, Kurz A (Hrsg.). Alzheimer Demenz. Grundlagen, Klinik und Therapie Berlin, Heidelberg, New York: Springer 1999: 129-152
- 41 Shoij M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, Shizuka M et al. Combination assay of CSF tau, A beta 1 - 40 and A beta 1 - 42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci. 1998; 158 134-140
- 42 Skoog I, Vanmechelen E, Andreasson L A, Palmertz B, Davidsson P, Hesse C, Blennow K. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration. 1995; 4 433-442
- 43 Tapiola T, Lethovirta M, Ramberg J, Helisalmi S, Linnaranta K, Riekkinen P, Soininen H. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. Neurology. 1998; 50 169-174
- 44 Tato R, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurol Neurosurg Psychiatry. 1995; 59 280-283
- 45 Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M, Lee D, Coria F, Chang L, Miller B, Lieberburg I, Schenk D. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 1995; 45 788-793
- 46 Wenham P R, Price W H, Blundell G. Apolipoprotein E genotyping by onestage PCR. Lancet. 1991; 337 1158-1159
Dr Peter Schönknecht
Psychiatrische Klinik der Universität Heidelberg
Voßstr. 4 69115 Heidelberg
Email: E-mail: Peter_Schoenknecht@med.uni-heidelberg.de